PE-22-28: Patient Information & Safety Notes
Also known as PE22-28
Other names: pe22-28, spadin-analogue
PE-22-28 is a synthetic 7-amino-acid peptide analogue of spadin, a naturally occurring peptide that inhibits the TREK-1 (tandem-pore-domain) potassium channel. TREK-1 inhibition has been proposed as a mechanism for antidepressant effects. PE-22-28 is a research compound with no human clinical trials.
In plain language
What PE-22-28 is used for
- Investigated in preclinical research for antidepressant and neuroprotective effects
Taking this medicine
How it is administered
- Subcutaneous injection
Read before you decide
Risks and precautions
Risks and warnings
- Mild headache, fatigue, nausea (extrapolated from animal and related compound data)
- Human safety unknown
Who should not take it
- Concurrent SSRI use (unknown interaction with serotonergic pathways)
- Pregnancy
- Age under 18
Common questions
Patient questions
Is PE-22-28 an approved antidepressant?
No. PE-22-28 has only been studied in animal models and has no human clinical trials. It is not FDA-approved for depression or any condition. Licensed providers can recommend FDA-approved antidepressants with established safety and efficacy profiles.
Related medications
Explore treatment hubs
This information is educational — not medical advice.
This page is provided for general educational purposes and summarizes publicly available data from sources such as the U.S. Food & Drug Administration. It is not a substitute for the judgment of a licensed clinician and should not be used to start, stop, or change any medication. It may be incomplete or out of date, and individual circumstances vary. Always talk with your prescriber or pharmacist about your specific medications and health conditions. If you think you may have a medical emergency, call 911.
Sources & References
Learn more about where our data comes from and how we write and review medical content.